Mehr Risiken als Nutzen? - Hormonersatztherapie in der Menopause

Zusammenfassung

Obwohl das Risiko für Herzkreislauferkrankungen bei Frauen in der Menopause, in der die natürliche Hormonproduktion sistiert, deutlich zunimmt, kann dieses Risiko nicht durch eine Hormonersatztherapie vermindert werden. Die alleinige postmenopausale Östrogentherapie ist mit einer leichten Erhöhung der Schlaganfallrate und der Rate an Lungenembolien verbunden, ohne einen günstigen Effekt auf die Prävalenz koronarer Ereignisse zu haben. Die Kombinationstherapie mit Östrogenen und Progesteron führt sowohl zu einer erhöhten Rate an Schlaganfällen und Lungenembolien als auch an koronaren Ereignissen, Brustkrebs und Demenz. Die alleinige und die kombinierte Hormongabe reduzieren die Frakturrate. Die Risiko-Nutzen-Abwägung ergibt jedoch insgesamt keinen günstigen Effekt. Bei der Medikamenten-Anamnese sollte auch die Hormonersatztherapie berücksichtigt und die Patientinnen entsprechend den neuesten, evidenzbasierten Richtlinien beraten werden. Aufgrund der Risiken, die mit der Hormonersatztherapie verbunden sind, ist es derzeit nur noch bei schweren, therapierefraktären Wechseljahrsbeschwerden gerechtfertigt, eine Hormonersatztherapie einzusetzen, wobei die Dauer so kurz wie möglich gehalten werden sollte. Da es keine therapeutischen Maßnahmen gibt, die sich in randomisierten Studien als wirksam und nebenwirkungsarm erwiesen haben, ist die Erforschung von Alternativen zur Behandlung von Menopausensymptomen von großer Bedeutung.

Summary

Inspite of the increased risk for coronary artery disease after menopause, in which hormone production ceases, the risk cannot be lowered by hormone replacement therapy. The use of estrogen alone is associated with a slight increase in stroke and pulmonary emboli without a positive effect on coronary event rate. The combined use of estrogens and gestagens is associated both with an increase in risk for stroke and pulmonary emboli as well as an increased risk for coronary events, breast tumors and dementia. The isolated estrogen use and the combined hormone use reduce the fracture rate. Risk-benefit-ratio does not show an overall beneficial effect. Obtaining the drug and medication history from the patient should always include hormone therapy. All patients should be advised according to evidence based guidelines. Due to the increased risk associated with hormone therapy at present it is only advised to use hormones in severe menopausal symptoms, refractory to other treatment modalities. The duration of use should be as short as possible. Since other in randomized studies proven, effective and well tolerated alternatives are not available, research on alternative treatments of menopausal symptoms is of utmost importance.

menopause - hormones - hormone replacement therapy - estrogen

Literatur

• 1 Angerer P, Störk S, Kothny W. et al. . Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomised controlled trial.  Arterioscl Thromb Vasc Biol. 2001;  21 262-268
• 2 Beral V. et al. . Breast cancer and hormone-replacement therapy in the Million Women Study.  Lancet. 2003;  362 419-427
• 3 Cauley JA, Robbins J, Chen Z. et al. . Effects of estrogen plus progestin on risk of fracture and bone mineral density: the women's health initiative investigators randomized trial.  JAMA. 2003;  290 1729-1738
• 4 Chlebowski RT, Hendrix SL, Langer RD. et al. . Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women.  JAMA. 2003;  289 3243-3253
• 5 Clemons M, Goss P. Estrogen and the risk of breast cancer.  N Engl J Med. 2000;  44 271-285
• 6 Collaborative Group on Hormonal Factors in Breast Cancer . Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer.  Lancet. 1997;  350 1047-1059
• 7 Gohlke-Bärwolf C, Regitz-Zagrosek V, Mueck R, Strasser A. Leitlinien der Deutschen Gesellschaft für Kardiologie: Stellenwert der Hormonersatztherapie zur Prävention der Koronaren Herzerkrankung bei Frauen.  Z Kardiol. 2002;  91 430-435
• 8 Gohlke-Barwolf C, von Schacky C. Stellenwert der Hormonersatztherapie zur Prävention der koronaren Herzerkrankung bei Frauen.  Z Kardiol. 2005;  94 III74-III78
• 9 Grady D, Herrington D, Bittner V. et al. . Cardiovascular disease outcomes during 6,8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).  JAMA. 2002;  288 49-57
• 10 Hodis HN, Mack WJ, Lobo RA. Postmenopausal hormone replacement therapy as antiatherosclerotic therapy.  Curr Atheroscler Rep. 2002;  4 52-58
• 11 Hoffmann M, Hammar M, Kjellgren K. et al. . Changes in women's attitudes towards and use of hormone therapy after HERS and WHI.  Maturitas. 2005;  52 11-17
• 12 Hulley S, Grady D, Bush T. et al. . Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.  JAMA. 1998;  280 605-613
• 13 Hulley S, Grady D. The WHI estrogen-alone trial - do things look any better?.  JAMA. 2004;  291 1769-1771
• 14 Michels KB, Manson JE. Postmenopausal hormone therapy: a reversal of fortune.  Circulation. 2003;  107 1830-1833
• 15 Mosca L, Appel IJ, Benjamin EJ. et al. . Evidence-based guidelines for cardiovascular disease prevention in women.  Circulation. 2004;  109 672-693
• 16 Mulnard RA, Cotman CW, Kawas C. et al. . Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study.  JAMA. 2000;  283 1007-1015
• 17 Ockene JK, Barad DH, Cochrane BB. et al. . Symptom experience after discontinuing use of estrogen plus progestin.  JAMA. 2005;  294 183-193
• 18 One Million Women Study Collaborators. Scarabin PY et al. Breast cancer and hormone-replacement therapy in the million women study.  Lancet. 2003;  362 419-427
• 19 Rapp SR, Espeland MA, Shumaker SA. et al. . Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.  JAMA. 2003;  289 2663-2672
• 20 Shumaker SA, Legault C, Rapp SR. et al. . Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.  JAMA. 2003;  289 2651-2662
• 21 The ESPRIT team . Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomized plazebo controlled trial.  Lancet. 2002;  360 2001-2008
• 22 The Women's Health Initiative Steering Committee . Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.  JAMA. 2004;  291 1701-1712
• 23 The Writing Group for the PEPI Trial . Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.  JAMA. 1995;  273 199-208
• 24 Torgerson DJ, Bell-Syer SEM. Hormone replacement therapy and prevention of novertebral fractures. A meta-analysis of randomized trials.  JAMA. 2001;  285 2891-2897
• 25 Viscoli CM, Brass LM, Kernan PM Sarech. et al. . A clinical trial of estrogen-replacement therapy after ischemic stroke.  N Engl J Med. 2001;  345 1243-1249
• 26 Vittinghoff E, Shlipak MG, Varosy PD. et al. . Risk factors and secondary prevention in women with heart disease: the heart and estrogen/progestin replacement study.  Ann Intern Med. 2003;  138 81-89
• 27 Wassertheil-Smoller S, Hendrix S, Limacher M. et al. . Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial.  JAMA. 2003;  289 2673-2684
• 28 Writing Group for the Women's Health Initiative Investigators . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.  JAMA. 2002;  288 321-333

1 Heart and Estrogen/progestin Replacement Study

2 Estrogen Replacement and Atherosclerosis

3 EStrogen in the Prevention of ReInfarction Trial

4 Women's Estrogen for Stroke Trial

5 Papworth Hormone Replacement Therapy and Atherosclerosis Survival Enquiry

6 Postmenopausal Hormone Replacement Against Atherosclerosis

7 Estrogen in the Prevention of Atherosclerosis

8 Women's International Study of Long Duration Oestrogen after Menopause

9 Women's Health Initiative

Anschrift der Verfasserin